Equities Analysts Offer Predictions for HURA FY2026 Earnings

Posted by Brenda Bartman on Aug 28th, 2026

TuHURA Biosciences, Inc. (NASDAQ:HURA – Free Report) – Equities researchers at Zacks Research raised their FY2026 earnings estimates for shares of TuHURA Biosciences in a note issued to investors on Tuesday, August 25th. Zacks Research analyst J. Vandermosten now anticipates that the company will post earnings of ($0.57) per share for the year, up from their prior estimate of ($0.64). The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.57) per share.

Several other equities research analysts have also issued reports on HURA. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Friday, July 17th. Citizens Jmp reissued a “market outperform” rating and set a $9.00 price objective on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Finally, Wall Street Zen downgraded TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, May 31st. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

View Our Latest Stock Report on TuHURA Biosciences

TuHURA Biosciences Price Performance

HURA opened at $2.13 on Friday. The company has a quick ratio of 0.18, a current ratio of 0.18 and a debt-to-equity ratio of 0.20. The stock has a market cap of $135.74 million, a price-to-earnings ratio of -3.94 and a beta of -0.01. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $3.43. The company’s 50-day moving average price is $2.27 and its two-hundred day moving average price is $2.11.

TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01.

Hedge Funds Weigh In On TuHURA Biosciences

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of TuHURA Biosciences by 1.6% in the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock valued at $5,629,000 after purchasing an additional 35,426 shares during the period. BlackRock Inc. bought a new position in TuHURA Biosciences in the 2nd quarter worth approximately $1,615,000. Geode Capital Management LLC grew its stake in TuHURA Biosciences by 6.4% in the 4th quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock valued at $501,000 after buying an additional 39,710 shares in the last quarter. State Street Corp grew its stake in TuHURA Biosciences by 4.9% in the 4th quarter. State Street Corp now owns 289,133 shares of the company’s stock valued at $219,000 after buying an additional 13,594 shares in the last quarter. Finally, Apollon Wealth Management LLC raised its holdings in TuHURA Biosciences by 17.7% during the 1st quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company’s stock valued at $283,000 after acquiring an additional 23,717 shares during the period. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

(Get Free Report)

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.